Okay.

So I actually have a little surprise for you.

Wha!

So I was doing my usual scan for COVID-19 research when I came across this and the lead researcher happened to be none other than Daniel Wrapp, who I interviewed for the SARS-CoV-2 to vaccine video a couple months ago.

He and his team discovered something pretty cool.

So I called him up with another friend on the line.

I'm actually about to bring someone into the chat there in the waiting room.

Um, and they are currently out standing in the field.

Wha!

So let's see, I'm wondering if you can tell Paco kind of what you and your team did and how he and his fellow camelids could be really helpful during this pandemic.

Paco, we immunized one of your friends named Winter with a vaccine against the MERS coronavirus and the SARS coronavirus.

And fortunately Winter was able to elicit antibodies, which hopefully will be really useful in treating COVID-19.

Winter is doing fine.

There's no need for concern.

She is grazing peacefully on a research farm in Belgium.

The antibodies that Winter produced are called nanobodies and nanobodies are about half the size of our antibodies.

And they combined to much smaller pockets and crevices on a virus than ours could.

So we're interested in how these nanobodies might be able to render the virus non-infectious.

How is this different from creating a vaccine or trying to create a vaccine?

We're passively administering antibodies that have been produced already so this is more of a treatment as opposed to vaccination.

And as long as it's circulating in the bloodstream, it will be able to protect against the SARS-CoV-2 infection, but also importantly, for people who are already infected and showing symptoms, it could help them fight the virus off more quickly.

So Paco, obviously this is very basic scientific research, but I want to know how you feel and what your emotions are about this type of research it's being performed.

He seems pretty unfazed.

I must say.

That is the most fun I'll have today.

Me too.